Open access peer-reviewed Edited Volume


Hridayesh Prakash

Amity University


TGFbeta VEGF FGF M-1 / M-2 polarization Th1/ Th2 Immune responses T-cell response Immuno metabolic programming iNOS+ M1 effector macrophages tumor vaccine tumor antigen presentation Tissue repair and regerenration CD 69 Purinergic receptors Dectin -1 Mannose Binding proteins CLEC-4 CLEC 7 CLA-1 & 2 CD169 /TCR-1+ macrophages

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Macrophages are ubiquitous and integrated part of both innate and adaptive immunity. These cells have been explored as extensive research tools in different contexts. Macrophages display a range of plasticity in their phenotype in different pathological conditions. Both peripheral and tissue macrophages together constitute the Reticuloendothelial system where they play major role in sensing pathogens and tumor antigens for their effective eradication. Out of various immune cells, macrophages display a range of plasticity which qualify them as one of potential target cells of body for the management of various human diseases clinically. Due to their plastic nature, these cells are literally involved in most of immunological and physiological process. Several groups including ours have demonstrated several MDR / XTR bacteria polarize M1 effector alveolar macrophages towards their M2 phenotype during their persistent infection. This seems to be the potential link to the sensitization for infection and may be for cancer development also.

Therefore the current mandate of research in macrophages immunobiology field mainly lies in the management of M1/M2 imbalance to minimize the risk of having cancer by chronic and persistent lung infection with intracellular pathogens like Chlamydia or Mycobacteria. This may be achieved by targeting major signaling pathways which drive M2 phenotype and are involved in cancer development e.g. Sphingolipids, Th2/Th17 responses.

In view of above, the major focus of this book is aimed to discuss research methodologies, resources / technologies by the dedicated biological community for identifying molecular signature involved in the polarization of M1 effector macrophages to M2 during disease. Within the umbrella of this ,the second major scope of this book is to explore how selective phenotype of macrophages would improve existing therapies with special emphasis at infection and cancer interface with special emphasis on lung cancers and various gastric inflammatory disease like IBD which are responsible for global mortality.

We invite scientists working on a cutting edge aspect of macrophages to submit their research to this project especially encouraging submissions that address macrophage-based therapeutic approaches.

Publishing process

Book initiated and editor appointed

Date completed: November 15th 2019

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline Extended: Open for Submissions

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Approved chapters written in full and submitted

Deadline for full chapters: February 4th 2020

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: April 24th 2020

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: June 23rd 2020

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Hridayesh Prakash

Amity University

Hridayesh Prakash, Ph.D is Associate Professor at Virology and Immunology Department, Amity University, India. Before starting his current position, he was Ramanujan Professor at University of Hyderabad during 2013-2017 and postdoctoral fellow in Germany during 2005-2013. His specializations are Tumor Immunology / Immunotherapy (lung and pancreatic cancer) and Cell based Immunotherapies, Host Apoptosis regulation, Signal Transduction, Pulmonary Infection Biology, Radiation Biology. His major research area is Immunotherapy of persistent Respiratory Infections and Gastric Cancer. He is unraveling therapeutic potential of macrophage against solid and established tumors and their contribution in various cancer directed interventions like radio / immune therapies. His second major interest is to understand how certain pathogens like H. pylori, Chlamydia and Mycobacteria sabotage host immunity with special emphasis on macrophage during chronic and persistent infections. Dr. Prakash has amply demonstrated that macrophages indeed represent potential target cell populations for translational medicine. He was able to demonstrate that adoptive transfer of tumor bearing mice with iNOs+ M1 macrophages offers an easy substitute of cumbersome high dose radiotherapy for the eradication of established, solid and refractory tumors of pancreas which is curse and death statement for the humankind. Within frame of this, he is also unraveling the impact of exchange of TAM with M1 macrophage on persistent infection driven cancer (adenocarcinoma) as well. He has published 32 papers including 2 book chapters. He received Young Scientist Award from Deference Research and Development organization, Govt of India and Ramanujan fellow award from Department of Science and Technology, Govt of India. Other than this Dr. Prakash is serving as member of Indian and German Immunology society. He is also serving as editorial board member of several international peer reviewed journals like F. Immunology, F. Microbiology. He has served as external reviewer for Austrian and Romanian Research Council and was a recipient of Travel from European society of Dermatological Research. Recently he has been elected as Fellow of Royal Society of Biology, London which is a caveat award conferred to him.

View profile

Book chapters authored 0

Books edited 0

Introducing your Author Service Manager

Mr. Josip Knapic

As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copy-editing and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question

Book will be abstracted and indexed in